Pyzchiva Injection, Solution
Product Images NDC 61314-654

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Pyzchiva (NDC 61314-654). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (130 Carton)

Packaging label for PYZCHIVA (ustekinumab-ttwe) Injection 130 mg/26 mL (5 mg/mL) for intravenous infusion only. The label includes dilution instructions and storage requirements. Manufactured by Samsung Bioepis Co., Ltd. for Sandoz Inc. It displays the NDC 61314-654-94 and includes barcode and batch information areas.*

FDA Label Image

45-carton-pfs (45 Carton Pfs)

Packaging label for Pyzchiva 45 mg/0.5 mL injection, a subcutaneous solution containing ustekinumab-ttwe. The label shows a single-dose prefilled syringe illustration and includes storage instructions, manufacturer details (Sandoz Inc. and Samsung Bioepis Co., Ltd.), and a barcode. The product is indicated for prescription use only.*

FDA Label Image

90mg-carton (90 Carton)

Packaging label for Pyzchiva (ustekinumab-ttwe) injection, solution 90 mg/mL. The label indicates a prefilled single-dose syringe for subcutaneous use. The product is manufactured by Samsung Bioepis Co., Ltd. and labeled by Sandoz Inc. The label includes storage instructions, a barcode, and manufacturer details.*

FDA Label Image

Figure-1 (Figure 1)

An instructional diagram showing a labeled subcutaneous injection syringe of PYZCHIVA (ustekinumab-ttwe). The syringe parts identified include the needle cover, needle, viewing window, label, syringe body, needle guard wings, plunger, and plunger head.*

FDA Label Image

Figure-2 (Figure 2)

An instructional diagram showing a close-up of a hand holding the upper part of an injection device, demonstrating how to position fingers to prepare or use the device. This is likely related to the administration of the PYZCHIVA injection solution.*

FDA Label Image

Figure-3 (Figure 3)

An instructional illustration showing a hand holding a prefilled syringe with a protective needle cap. The image emphasizes pulling the cap straight off the syringe as indicated by an upward arrow, demonstrating how to prepare the injection device for use.*

FDA Label Image

Figure-a-vial (Figure A Vial)

An instructional diagram showing components typically required for subcutaneous injection using PYZCHIVA (ustekinumab-ttwe). The illustration includes an adhesive bandage, antiseptic wipes, cotton ball or gauze pad, PYZCHIVA vial, syringe with attached needle, and an FDA-cleared sharps disposal container for safe needle disposal.*

FDA Label Image

Figure-a (Figure A)

Illustration showing the components included with PYZCHIVA prefilled syringe for subcutaneous injection. Items depicted are the prefilled syringe, adhesive bandage, antiseptic wipes, cotton ball or gauze pads, and an FDA-cleared sharps disposal container.*

FDA Label Image

Figure-b-vial (Figure B Vial)

Illustration showing recommended subcutaneous injection sites for PYZCHIVA (ustekinumab-ttwe). Highlighted areas include the thigh, abdomen (excluding a 2-inch area around the navel), upper arms, and the lower back near the buttocks. The diagram helps guide patients on appropriate injection locations for this solution.*

FDA Label Image

Figure-b (Figure B)

An instructional diagram of a PYZCHIVA injection pen showing labeled parts including needle cover, needle, viewing window, body, label, needle guard wings, plunger, and plunger head. The diagram visually breaks down the components of the subcutaneous injection device for ustekinumab-ttwe.*

FDA Label Image

Figure-c-vial (Figure C Vial)

An instructional illustration showing a vial with its cap being removed by lifting it upward and off the vial. The image depicts the opening of a vial, likely for preparing an injection.*

FDA Label Image

Figure-c (Figure C)

An illustration showing recommended subcutaneous injection sites on the human body for PYZCHIVA injection, solution. The marked areas include the front of the thighs, the abdomen excluding the navel area, the upper outer arms, and the buttocks.*

FDA Label Image

Figure-d-vial (Figure D Vial)

An instructional illustration showing two hands handling a small vial, with one hand gripping the vial and the other lifting or removing its cap. The vial appears to contain a liquid medication, suggesting a step in preparing an injection, such as with the PYZCHIVA (ustekinumab-ttwe) solution for subcutaneous injection.*

FDA Label Image

Figure-d (Figure D)

An instructional illustration showing two hands preparing a prefilled syringe injection device. One hand holds the syringe while the other hand removes a protective cap by pulling it straight off, indicated by double-headed arrows. The image demonstrates safe handling before subcutaneous injection.*

FDA Label Image

Figure-e-vial (Figure E Vial)

An instructional illustration showing two hands demonstrating the removal of the cap from a prefilled syringe. The arrows indicate the directions to pull the cap off from the syringe prior to injection.*

FDA Label Image

Figure-e (Figure E)

An instructional line drawing showing a hand holding a syringe, positioned to perform a subcutaneous injection. The image demonstrates the proper grip and angle for administering the injection.*

FDA Label Image

Figure-f-vial (Figure F Vial)

An instructional illustration showing two hands preparing a syringe by drawing liquid from a small vial, demonstrating the process of extracting an injection solution, likely representing subcutaneous administration preparation.*

FDA Label Image

Figure-f (Figure F)

An instructional illustration showing a hand holding a syringe angled at 45 degrees for subcutaneous injection into the skin of the opposite arm. The image demonstrates proper needle positioning for self-administration.*

FDA Label Image

Figure-g-vial (Figure G Vial)

An instructional line drawing showing hands holding a syringe and a vial. One hand holds the vial upside down, and the other hand holds the syringe needle inserted into the vial, depicting the process of drawing medication from the vial into the syringe.*

FDA Label Image

Figure-g (Figure G)

An instructional illustration showing hands holding a syringe with labeled "needle guard wings," highlighting the component designed to provide safety during injection. The image is related to the use of PYZCHIVA, a subcutaneous injection solution of ustekinumab-ttwe.*

FDA Label Image

Figure-h-vial (Figure H Vial)

An instructional illustration showing how to withdraw medication from a vial into a syringe using two hands. One hand holds the vial upside down, while the other hand pulls back the syringe plunger to draw the solution.*

FDA Label Image

Figure-h (Figure H)

An illustration showing a hand holding a prefilled syringe and pulling off the cap, demonstrating preparation steps for subcutaneous injection of PYZCHIVA (ustekinumab-ttwe) injection solution.*

FDA Label Image

Figure-i-vial (Figure I Vial)

Illustration showing the proper subcutaneous injection technique for PYZCHIVA (ustekinumab-ttwe). The image depicts a hand holding a syringe at a 45-degree angle to the skin of the upper thigh, with the other hand gently pinching the skin to administer the injection.*

FDA Label Image

Figure-j-vial (Figure J Vial)

An instructional illustration showing a hand holding a syringe with the needle pointing downward, indicating the step of expelling air or preparing the syringe before injection.*

FDA Label Image

Figure4 (Figure4)

A line graph titled 'PsA STUDY 1' showing patient response percentages over 24 weeks. The x-axis represents time in weeks (0 to 24), and the y-axis shows the percentage of patients (0% to 60%). Three lines indicate different study groups: placebo (open circles), ustekinumab 45 mg (gray triangles), and ustekinumab 90 mg (black squares). Both ustekinumab groups show higher patient response rates compared to placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.